Beyond the guidelines in the treatment of peripheral T-cell lymphoma: New drug development

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 4, 2008, Pages 428-435

  Chen, Andy I ^a   Advani, Ranjana H ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antimetabolites; Histone deacetylase inhibitor; Immunotherapy; Peripheral T cell lymphoma; Targeted therapy

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 7 HYDROXYSTAUROSPORINE; ALEMTUZUMAB; BORTEZOMIB; CISPLATIN; CLADRIBINE; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLIC ACID; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; LENALIDOMIDE; MDX 060; METHYLPREDNISOLONE; NELARABINE; PENTOSTATIN; PRALATREXATE; PREDNISONE; RITUXIMAB; ROMIDEPSIN; SGN 30; SIPLIZUMAB; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; ZANOLIMUMAB;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOPENIA; DRUG TARGETING; HUMAN; HYPERSENSITIVITY REACTION; HYPOALBUMINEMIA; INFECTION; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; NEUTROPENIA; PATHOGENESIS; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; QT PROLONGATION; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE;

EID: 43149105157     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0032     Document Type: Review

References (59)